156 related articles for article (PubMed ID: 16950004)
1. Chapter 19: Cost-effectiveness of cervical cancer screening.
Goldie SJ; Kim JJ; Myers E
Vaccine; 2006 Aug; 24 Suppl 3():S3/164-70. PubMed ID: 16950004
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
3. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
Franco EL; Cuzick J; Hildesheim A; de Sanjosé S
Vaccine; 2006 Aug; 24 Suppl 3():S3/171-7. PubMed ID: 16844268
[TBL] [Abstract][Full Text] [Related]
4. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.
Wheeler CM
Nat Clin Pract Oncol; 2007 Apr; 4(4):224-35. PubMed ID: 17392713
[TBL] [Abstract][Full Text] [Related]
5. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
6. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.
Ronco G; Brezzi S; Carozzi F; Dalla Palma P; Giorgi-Rossi P; Minucci D; Naldoni C; Segnan N; Zappa M; Zorzi M; Cuzick J;
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S230-2. PubMed ID: 17822751
[TBL] [Abstract][Full Text] [Related]
7. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
Wright TC; Bosch FX; Franco EL; Cuzick J; Schiller JT; Garnett GP; Meheus A
Vaccine; 2006 Aug; 24 Suppl 3():S3/251-61. PubMed ID: 16950014
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
[TBL] [Abstract][Full Text] [Related]
10. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
11. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for cervical cancer prevention in Latin America and the Caribbean.
Muñoz N; Franco EL; Herrero R; Andrus JK; de Quadros C; Goldie SJ; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 11():L96-L107. PubMed ID: 18945407
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
14. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
16. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
18. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
19. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.
Sankaranarayanan R; Bhatla N; Gravitt PE; Basu P; Esmy PO; Ashrafunnessa KS; Ariyaratne Y; Shah A; Nene BM
Vaccine; 2008 Aug; 26 Suppl 12():M43-52. PubMed ID: 18945413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
